We report a case of a possible interaction between itraconazole, phenobarbital and carbamazepine. The first plasma itraconazole concentration, measured when the patient had been taking phenobarbital for 2 months, was very low. The second measurement, 2 months after withdrawing phenobarbital, was higher but below the therapeutic range. However, carbamazepine, a well known enzyme inducer, had been initiated 15 days before. 20 days after carbamazepine was withdrawn, the itraconazole concentration 4 hours after administration was near the lower end of the therapeutic range. The mechanism of this possible interaction is probably the same for phenobarbital and carbamazepine, involving hepatic microsomal enzyme system induction.
Carbamazepine Valproic Acid Itraconazole Phenobarbital Therapeutic Range
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Blomley M, Teare EL, De Belder A, Thway Y, Weston M. Itraconazole and antituberculosis drugs. Lancet 336: 1255, 1990PubMedCrossRefGoogle Scholar
Bowdle TA, Levy RH, Cutles RE. Effects of carbamazepine on valproic acid in normal man. Clinical Pharmacology and Therapeutics 26: 629–634, 1979PubMedGoogle Scholar
Cohen J. Laboratory monitoring of antifungal chemotherapy. Lancet 337: 1577–1580, 1991Google Scholar
Dupont B, Drouhet E. Early experience with itraconazole in vitro and in patients: pharmacokinetics studies and clinical results. Reviews of Infectious Diseases 9(Suppl. 1): 71–76, 1987CrossRefGoogle Scholar
Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344, 1989PubMedCrossRefGoogle Scholar
Hansen JM, Siersback-Nielsen K, Skovsted L. Carbamazepine induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 539–543, 1971PubMedGoogle Scholar
Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazole in the management of onychomycosis. British Journal of Dermatology 119: 359–366, 1988PubMedCrossRefGoogle Scholar
Kramer MR. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Annals of Internal Medicine 113: 327–329, 1990PubMedGoogle Scholar
Lai AA, Levy RH, Cutler RE. Time course of interaction between carbamazepine and clonazepam in normal man. Clinical Pharmacology and Therapeutics 25: 316–323, 1978Google Scholar
Lyman CA, Walsh TJ. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic application. Drugs 44: 9–35, 1992PubMedCrossRefGoogle Scholar
Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. British Medical Journal 301: 669, 1990PubMedCrossRefGoogle Scholar